Compound versions of weight loss drugs will no longer be available, FDA rules
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...
Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...
Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
FDA update could extend Hims & Hers’ compounding timeline, says BofA
BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...